Welcome to the 2nd Donor Selection & Cell Source Summit
Together, We Can Revolutionize the Future of Allogeneic Therapies & Significantly Enhance Patient Outcomes
Are our donor selection criteria robust enough to meet this critical field's growing demands and challenges?
As the clinical landscape for allogeneic therapies continues to evolve, the challenging reality of achieving true scalability is setting in for the field, with all eyes turning to the backbones of these universal therapies to ensure a high-quality and scalable product can be achieved through a well-thought-out donor plan.
The 2nd Donor Selection & Cell Source Summit provided an unparalleled opportunity to delve into the latest global regulatory requirements and variations in donor testing, cutting-edge genome sequencing data driving donor selection, establishing new partnerships to streamline logistical coordination with donation sites and ensuring exclusive access to chosen donor pools.
The ONLY Meeting Keeping Donors at the Heart of the Conversation
We Collaborated with Bristol Myers Squibb, ImmuneBridge, Deverra Therapeutics & more!
You joined us in 2024 to participate in this industry-defining forum specifically designed to inspire and facilitate transparent and interactive discussions on transforming off-the-shelf cell therapies right from the start.
By refining our donor selection processes today, we can revolutionize the future of allogeneic therapies and significantly enhance patient outcomes.
2024 Expert Speakers
Our 2024 Partners
I appreciate the intimacy of the conference size, which fosters more dialogue and interaction with fellow participants''
Senior Manager - Process Data Systems & Analytics, AlloVir - 2023 Attendee